VaxSen

VaxSen is a biotechnology company focused on the development of next-generation vaccines for infectious diseases, with a primary emphasis on respiratory viruses. The company utilizes a proprietary nanoparticle-based platform designed to enhance the immune response and provide broader protection against evolving viral strains. Their lead programs target Respiratory Syncytial Virus (RSV) and SARS-CoV-2, aiming to address significant unmet needs in global public health. By leveraging advanced protein engineering and formulation technologies, VaxSen seeks to create vaccines that are more stable, easier to manufacture, and highly effective across diverse patient populations. The company is currently advancing its candidates through pre-clinical validation to support future clinical entry.